《藍籌業績》中國生物製藥(01177.HK)首三季純利22.6億人民幣升2.5% 季度息2港仙
中國生物製藥(01177.HK)公布截至今年9月底止首三季業績,營業額193.21億元人民幣(下同),按年升22.8%。純利22.56億元,按年升2.5%;每股盈利17.92分。派季度息2港仙,上年同期派2港仙。
期內肝病用藥佔收入比重最大,達25.7%,抗腫瘤用藥佔約21.8%,心腦血管用藥則佔12.9%;新產品銷售佔本集團總收入約 20.6%。
中生製藥表示,期內行業 4+7藥品集中採購持續落地鋪開,入選品種市場銷量增長明顯,但大幅降價,利潤增速減緩。展望全年,外部環境依然充滿不確定因素,相信帶量採購會從試點擴大到全國,會進一步影響入選品種的收入和利潤,但公司有信心鞏固市場地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.